20 results on '"Blue, Brandon"'
Search Results
2. Guarding the Heart in an Era of “Tachy-CAR-T”
3. MM-059 Incidence and Risk Factors Associated With Bleeding Following Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
4. Culturally Responsive Care Delivery in Oncology: The Example of Multiple Myeloma
5. Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis
6. POSTER: MM-059 Incidence and Risk Factors Associated With Bleeding Following Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
7. Hematopoietic Recovery after Anti-B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor T Cell Therapy (CAR T), Idecabtagene Vicleucel (Ide-cel), for Relapsed/ Refractory Multiple Myeloma (RRMM)
8. Anti-BCMA CAR T-Cell Commercial Slot Allocation in Patients with Relapsed/Refractory Multiple Myeloma: Insights from a Single Center Experience
9. Fludarabine Exposure Impact on Safety and Efficacy of Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma (RRMM)
10. Baseline Levels of Systemic Inflammatory Markers Interleukin 6 and Ferritin Are Associated with Toxicities and Progression-Free Survival in Multiple Myeloma Patients Treated with Idecabtagene Vicleucel
11. Observation of Wigner cusps in a metallic carbon nanotube
12. Scanning tunneling microscopy and spectroscopy of NiTe2
13. Socioeconomic and Racial Disparity in Chimeric antigen receptor T cell (CART)Therapy Access
14. Adding cyclophosphamide to bortezomib and dexamethasone was not associated with improved outcomes of patients with newly diagnosed light chain amyloidosis: a retrospective study
15. Cytopenia and Infection Early after Standard of Care Idecabtagene Vicleucel in Multiple Myeloma
16. Understanding Physician Referral for Chimeric Antigen Receptor T-Cell Therapy
17. Marrow Myeloma Burden and Idecabtagene Vicleucel Outcomes in the Standard of Care Setting
18. CARDIAC EVENTS AFTER ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR T-CELL (IDECABTAGENE VICLEUCEL) FOR MULTIPLE MYELOMA
19. Impact of Obesity on Lymphodepletion and Outcomes Following Idecabtagene Vicleucel in Multiple Myeloma
20. Outcomes of Autologous Stem Cell Transplant in Lymphoma Patients with Mild Renal Impairment
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.